Drug Type Trispecific killer cell engager (TriKE) |
Synonyms CAM161519, GTB7550, GTB7750 TRIKE |
Target |
Mechanism CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators), CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), IL15R agonists(Interleukin-15 receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Preclinical | US | 10 Jun 2022 |